

References

I-151

1. Katzberg H, Rasutis V, Bril V. Home iVIG for CIDP: A Focus on Patient Centered Care. *Can J Neurol Sci*. 2013;40:384-388.
2. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: safe clinically effective, patient preferred, and cost saving. *Healthcare*. 2016.
3. Elstein D, Abrahamov A, Oz A, et al. 13,845 home therapy infusions with velaglucerase alfa exemplify safety of velaglucerase alfa and increased compliance to every-other-week intravenous enzyme replacement therapy for Gaucher disease. *Bld Cell Mol Dis*. 2015;415-418.
4. American Academy of Allergy Asthma and Immunology. Eight Guiding Principles for Effective Use of IVIG for Patients with Primary Immunodeficiency. December 2011.
5. ASHP Guidelines on Home Infusion Pharmacy Services, 2013. Accessed September 2, 2016.
6. Home Infusion Therapy, CMT: CMT-0009(SR). MCG Care Guidelines, 20th edition, 2016.
7. Doran JP, Alraqi S, Callanan I, Fitzgerald O, Bresnihan B, Veale DJ. An audit of hospital based outpatient infusions and a pilot program of community-based monoclonal antibody infusions. *Ir J Med Sci*. 2009;497-501.
8. Huynh TK, Ostergaard A, Egsmose C, Madsen OR. Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis. *Patient Preference and Adherence*. 2014;3-99.
9. Stuby U, Biesenbach G, Pieringer H. Administration of infliximab in general practitioners' offices is safe. *Clin Rheumatol*. 2007;1863-1866.
10. Condino AA, Fidanzo S, Hoffenberg EJ. A Home Infliximab Infusion Program. *Pediatr Gastroenterol Nutr*. 2005;67-69.
11. Johnson R, Freeman EN. Addressing Costs and Continuity of Care through Innovative Solutions for Infused Therapies: A Collaborative Experience with Infliximab. *Am Health Drug Benefits*. 2011;4(1):39-46.
12. Kuin S, Stolte SB, van den Brink GR, et al. Remicade infusions at home: an alternative setting of infliximab therapy for patients with Crohn's disease. *Eur J Gastroenterol Hepatol*. 2016;222-225.
13. MCG™ Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT:CMT-0009(SR).
14. Daly M, Zimmer A, Stickling J, Daikeler T, & Grossmann F. COVID-19 driven care changes in high risk patients from an outpatient to a community setting: A cross-sectional study. *Pflege*. 2020;33:219-227.
15. Checkley L, Kristofek L, Kile S & Bolgar W. Incidence and management of infusion reactions to infliximab in an alternate care setting. *Dig Dis Sci* 2019;64:855-862.